A cross-sectional analysis of research waste in randomized controlled trials on postoperative cognitive dysfunction Authors: Jiyang Li, Xinxing Fei, Qiuyu Zhou, Weiyi Li, Zhangyu Xu, Jianxiong Wang, Yaqian Gao, Yue Hu Published: 2026 ABSTRACT AbstractPostoperative cognitive dysfunction (POCD) is a common postoperative complication in older adults, with high-quality evidence mainly from randomized controlled trials (RCTs). However, research heterogeneity in this field may lead to significant waste, yet a systematic assessment is lacking. To analyze characteristics of POCD-related RCTs, quantify research waste, and explore influencing factors. This cross-sectional study searched ClinicalTrials.gov to identify registered RCTs initiated since 2000 that involved adult surgical patients and assessed postoperative cognitive function as a primary or secondary outcome. We extracted trial characteristics and evaluated publication status, reporting quality, and risk of design flaws. Analyses included descriptive statistics, chi-square tests, and logistic regression. Among 53 included RCTs, trials were predominantly drug-based (94.34%), single-center (75.47%), and non-department funded (98.11%), with Asia being the largest contributing region (43.40%). Of 43 trials completed by 2023, only 7 (16.3%) were published, mostly from North America/Europe (P = 0.012). Reporting quality was good, but 42.9% had design flaws. Research waste reached 90.7% (39/43), and Asian-origin trials showed the highest waste rate (51.28%, P = 0.028). Regression suggested trends linking larger sample sizes/multicenter designs to lower waste and non-Western regions to higher waste/lower publication, but these were not statistically significant. In conclusion, POCD RCTs exhibit high research waste with notable geographic imbalance. Waste appears multifactorial. Enhancing methodological rigor and improving research translation mechanisms are needed to optimize resource use and evidence quality.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54586-x.Keywords: Postoperative cognitive dysfunction, Cognitive dysfunction, Postoperative cognitive complications, Surgery, Randomized controlled trials, Research wasteSubject terms: Diseases, Health care, Medical research Introduction Postoperative cognitive dysfunction (POCD) is a common central nervous system complication in elderly patients, primarily manifesting as new or worsening impairments in memory, attention, and executive function1. POCD is closely associated with prolonged hospital stays, functional decline, reduced quality of life, and an increased long-term risk of dementia and mortality, constituting a significant public health concern2. With the global aging population and rising surgical volumes, the disease burden of POCD is increasing, making effective prevention and treatment an urgent priority for clinical research3,4. The pathogenesis of POCD is widely recognized as multifactorial, involving a complex interplay of surgery-induced inflammation, anesthetic neurotoxicity, and patient-specific vulnerabilities such as preexisting cognitive impairment and comorbidities5,6. Among these, the systemic inflammatory response triggered by surgical trauma is considered a pivotal mechanism. Pro-inflammatory cytokines can disrupt the blood-brain barrier and promote neuroinflammation, ultimately leading to neuronal dysfunction and cognitive deficits7. Glumac et al. demonstrated that preoperative corticosteroid administration effectively attenuated the postoperative inflammatory response and subsequently reduced the long-term incidence and severity of POCD8. While these mechanistic insights provide a strong rationale for clinical trials, the successful translation of such interventions into clinical practice relies heavily on the methodological rigor and quality of the underlying Randomized Controlled Trials (RCTs). RCTs are the gold standard for evaluating the efficacy of interventions. They are crucial for exploring the pathophysiology of POCD, validating neuroprotective strategies, and optimizing perioperative management, especially for elderly patients. In recent years, numerous RCTs have focused on pharmacological interventions, anesthesia techniques, and comprehensive perioperative care9–11. However, these studies exhibit significant heterogeneity in methodological design, implementation quality, and evidence translation. Many trials, hampered by inadequate sample sizes, inconsistent diagnostic criteria, short follow-up periods, or varying assessment tools, produce results that are difficult to compare and synthesize, limiting the development of high-quality evidence-based guidelines12,13. Research waste refers to the failure to translate finite research resources into reliable, applicable clinical evidence due to design flaws, poor implementation, non-publication of results, or opaque reporting14. In POCD research, methodological heterogeneity combined with pathophysiological complexity heightens the risk of waste. The lack of unified diagnostic criteria and assessment systems impedes evidence synthesis15, while intervention designs targeting multiple confounding factors and specific neuropharmacological properties are often flawed, leading to trials that fail to produce clear, translatable evidence16,17. Furthermore, a substantial number of completed RCTs remain unpublished, and the quality of published reports varies considerably, potentially further undermining the completeness and reliability of the evidence base. Currently, there is a lack of systematic assessment of research waste in POCD-related RCTs. Such an evaluation is critical for identifying methodological weaknesses, optimizing future trial design, and improving the utilization of research resources. Therefore, this study hypothesizes that a significant proportion of POCD-related RCTs registered on ClinicalTrials.gov suffer from avoidable methodological flaws and incomplete reporting, leading to substantial research waste that hinders the translation of findings into clinical practice. To test this hypothesis, we aim to systematically analyze POCD-related RCTs, describe their basic characteristics, quantify the proportions of non-publication and inadequate reporting, identify factors associated with research waste, and provide empirical evidence and strategic recommendations for conducting more efficient and reliable POCD clinical research in the future. Methods Study design and data source This cross-sectional study followed STROBE guidelines and used data from ClinicalTrials.gov. The final search was conducted on February 28, 2026. We performed two independent searches within the “Condition/disease” field of the registry interface: one using the term “postoperative cognitive dysfunction” and the other using “postoperative cognitive impairment”. No Boolean operators were employed, as these were separate, sequential searches whose results were subsequently merged (Fig. 1). The search period spanned from January 2000 to the final search date, with no language restrictions. Reference list screening was omitted as the data source was the registry itself. Flowchart of study selection and data analysis for RCTs related to POCD. RCTs: randomized controlled trials; POCD: postoperative cognitive dysfunction. Inclusion and exclusion criteria Inclusion criteria: (1) Study type: RCT; (2) Participants: adult surgical patients (≥ 18 years); (3) Primary or secondary outcomes explicitly include assessment of postoperative cognitive function. Exclusion criteria (1) Non-interventional studies; (2) Early-phase trials (Phase I or II); (3) Studies unrelated to POCD. Data extraction Two researchers independently performed data extraction and cross-checking. Discrepancies were resolved through discussion or consultation with a third researcher. Based on the exported data, the following information was extracted: (1) Basic trial characteristics: start time, NCT number. (2) Participant characteristics: target sample size, patient age range. (3) Trial design characteristics: intervention type, control setting, blinding method, number of arms, study purpose. (4) Implementation characteristics: number of recruiting centers (single-center/multicenter), region of principal investigator (PI). (5) Funding source: categorized as “Departmental” or “Industry or other external”, where Departmental corresponds to U.S. National Institutes of Health and other federal agencies, while Industry or other external includes industry sponsors such as pharmaceutical and device companies, as well as individuals, universities, and community-based organizations. Outcome definitions Publication status Searches were conducted in PubMed, Web of Science, and Google Scholar using the NCT number and investigator names to confirm if a full-text article was published in a peer-reviewed journal. If not found, the principal investigator was contacted via registry information. Studies not published by February 28, 2026, were recorded as “unpublished”. Reporting adequacy The assessment of reporting quality was restricted to published articles, as registry records alone do not provide sufficient detail to evaluate reporting completeness. For published articles, reporting quality was assessed using the CONSORT statement. The percentage of compliant items was calculated, with ≥ 75% considered “adequately reported”. Design flaws Methodological quality was assessed exclusively for published RCTs, as the necessary detailed information for such evaluation was unavailable in registry records alone. The methodological quality of published RCTs was assessed using the Cochrane Risk of Bias tool, which covers the randomization process, intervention adherence, missing outcome data, outcome measurement, and selective reporting. Additionally, trial protocols or article introductions were checked for citations to and discussion of relevant POCD reviews, systematic reviews, or meta-analyses to assess whether the study was based on the best available evidence. Studies with any “high risk of bias” or “no citation of relevant reviews” were considered to have “avoidable design flaws”. Research waste: Defined as meeting any of the following criteria: (1) The trial was completed but unpublished (using a primary completion date before December 31, 2023, accounting for the typical lag from completion to publication); (2) Published but inadequately reported; (3) Published but with avoidable design flaws. Of note, unpublished trials were classified as research waste based solely on their non-publication status, without further assessment of reporting adequacy or design flaws. Statistical analysis Categorical variables were described using frequencies (percentages). Differences between groups for categorical variables were compared using the Chi-square test or Fisher’s exact test. Univariate logistic regression was used to examine associations between trial characteristics and the risk of publication or research waste, expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Variables that achieved statistical significance in the univariate analysis were subsequently included in a multivariate logistic regression model; a full inclusion approach was employed for the multivariate model. All statistical tests were two-sided, and a P-value < 0.05 was considered statistically significant. All analyses were performed using Prism 10.1.2. Results Trial characteristics overview Fifty-three eligible RCTs were included (Fig. 1and Table 1). In terms of start time, trials registered between 2010 and 2019 were most concentrated (54.72%). The included trials were highly focused on pharmacological interventions (94.34%). Based on a sample size cutoff of 300 (median Q3), trials were divided into small (< 300, 52.83%) and large (≥ 300, 47.17%) groups. Implementation-wise, over three-quarters were single-center (75.47%) and predominantly funded by industry or external sources (98.11%). Principal investigators were primarily based in Asia (43.40%), followed by North America (26.42%) and Europe (22.64%). Table 1Characteristics of RCTs after 2000 years.CharacteristicRCTs, No. (%) (N = 53)Start time2000–20091018.87%2010–20192954.72%After 20191426.42% Interventions Drug5094.34%Non-drug35.66% Study design Parallel group5298.11%Non-Parallel group11.89% No. of arms 24381.13%3815.09%≥ 423.77% Blinding None/open label35.66%Single59.43%Double1833.96%Triple1018.87%Quadruple1732.08% Recruitment National4992.45%International00.00%Missing47.55% No. of centers Single center4075.47%Multicenter815.09%Missing59.43% No. of participants <3002852.83%≥ 3002547.17% Region of PI North American1426.42%Europen1222.64%Asian2343.40%Other47.55% Primary purpose Prevention3362.26%Treatment1120.75%Others (screening, supportive care, diagnosis, etc.)916.98% Funding Departmental11.89%Industry or other external5298.11%No.: number; PI: principal investigator. Characteristics of RCTs after 2000 years. No.: number; PI: principal investigator. Publication Status of Completed Trials Among the 43 trials completed by December 31, 2023, only 7 RCTs were published (Table 2). All published trials involved pharmacological interventions and received industry or other external funding. Regarding trial design, none of the published studies used an open-label or single-blind design; most employed multiple blinding (double-, triple-, or quadruple-blind) and were primarily two-arm or multi-arm parallel studies aimed at POCD prevention. All published trials originated from North America, Europe, or other regions. Notably, none of the 20 Asian-origin trials were published, a difference reaching statistical significance (P = 0.012) (Fig. 2). Regarding the trial scale, the number of published trials was relatively balanced between large (≥ 300 participants) and small sample sizes. Overall, single-center studies constituted the majority of published trials. Table 2Characteristics of RCTs completed before 2023.Publish status P Design flawP Research waste* P Published (7)Not published (36)Absence (4)Presence (3)Absence (4)Presence (39) Start time > 0.999> 0.999> 0.999Before 2009 (Include)114.29%925.00%125.00%00.00%125.00%923.08%After 2009685.71%2775.00%375.00%3100.00%375.00%3692.31% Interventions > 0.999> 0.999> 0.999Drug7100.00%3391.67%4100.00%3100.00%4100.00%3692.31%Non-drug00.00%38.33%00.00%00.00%00.00%37.69% No. of arms > 0.9990.429> 0.9992685.71%3083.33%4100.00%266.67%4100.00%3282.05%3114.29%616.67%00.00%133.33%00.00%717.95% Blinding > 0.999> 0.999> 0.999None/open label00.00%25.56%00.00%00.00%00.00%25.13%Single00.00%38.33%00.00%00.00%00.00%37.69%Double342.86%1336.11%250.00%133.33%250.00%1435.90%Triple228.57%616.67%250.00%00.00%250.00%615.38%Quadruple228.57%1233.33%00.00%266.67%00.00%1435.90% Recruitment > 0.999> 0.999> 0.999National7100.00%3288.89%4100.00%4133.33%4100.00%3692.31%International00.00%00.00%00.00%00.00%00.00%00.00%Missing00.00%411.11%00.00%00.00%00.00%410.26% No. of centers > 0.999> 0.999> 0.999Single center685.71%2672.22%6150.00%26866.67%375.00%52133.33%Multicenter114.29%616.67%125.00%6200.00%125.00%1230.77%Missing00.00%411.11%00.00%4133.33%00.00%820.51% No. of participants > 0.999> 0.999> 0.999<300342.86%1850.00%375.00%18600.00%250.00%3692.31%≥ 300457.14%1850.00%4100.00%18600.00%250.00%3692.31% Region of PI 0.012> 0.9990.028North American342.86%925.00%375.00%133.33%250.00%1025.64%Europen342.86%616.67%375.00%266.67%125.00%820.51%Asian00.00%2055.56%00.00%00.00%00.00%2051.28%Other114.29%12.78%125.00%00.00%125.00%12.56% Primary purpose > 0.999> 0.9990.602Prevention571.43%2363.89%250.00%3100.00%250.00%2666.67%Treatment114.29%719.44%125.00%00.00%125.00%717.95%Others (screening, supportive care, diagnosis, etc.)114.29%616.67%125.00%00.00%125.00%615.38% Funding Departmental00.00%00.00%00.00%00.00%00.00%00.00%Industry or other external7100.00%36100.00%4100.00%3100.00%4100.00%39100.00% Study design Parallel group7100.00%36100.00%4100.00%3100.00%4100.00%39100.00%Non-Parallel group00.00%00.00%00.00%00.00%00.00%00.00%*Research waste was defined as the presence of any of the following: unpublished status, inadequate reporting, or avoidable design flaws. In our study, no trial was classified as inadequately reported. No.: number; PI: principal investigator. Characteristics of RCTs completed before 2023. *Research waste was defined as the presence of any of the following: unpublished status, inadequate reporting, or avoidable design flaws. In our study, no trial was classified as inadequately reported. No.: number; PI: principal investigator. Proportion of published RCTs related to POCD by geographic region. RCTs: randomized controlled trials; POCD: postoperative cognitive dysfunction. Reporting Completeness and Design Flaws In terms of reporting completeness, all 7 published RCTs strictly adhered to the CONSORT 2010 checklist (Table S1), with only the “access to the study protocol” item having a lower reporting rate (42.86%, 3/7), which did not affect overall reporting completeness. Furthermore, all published studies cited review or meta-analysis articles. Regarding design flaws, 3 trials had them, all stemming from “other bias,” while 4 had none (Figure S1). There were no statistically significant differences in baseline characteristics, including start time, intervention type, sample size, blinding, region, study purpose, and funding source, between trials with and without design flaws. Prevalence and Characteristics of Research Waste Among the 43 trials completed by the cutoff date, the proportion of research waste was extremely high at 90.7% (39/43), with only 4 trials (9.3%) classified as having no research waste (Table 2). Comparison of baseline characteristics between trials with and without waste found a statistically significant difference only for the variable “region of the principal investigator” (P = 0.028). Specifically, among the 39 trials with waste, those originating from Asia accounted for the largest proportion (20 trials, 51.28%). For all other characteristics, no statistically significant differences were observed between the two groups. Factors Associated with Publication and Waste Logistic regression analysis was used to analyze associations of key study characteristics with “publication status” and with “research waste status.” For publication status (Table 3), a large sample size (≥ 300 participants) showed a positive trend towards publication (OR = 2.00, 95% CI: 0.34–15.94, P = 0.459). Conversely, trials originating from non-European/American regions (primarily Asia) showed a negative trend towards publication (OR = 0.16, 95% CI: 0.01–1.11, P = 0.106). However, these associations did not reach statistical significance. Similarly, in the regression analysis for research waste status (Table 4), trials originating from non-European/American regions showed a trend towards increased waste risk (OR = 2.12, 95% CI: 0.19–48.07, P = 0.555). Meanwhile, multicenter design (OR = 0.41, 95% CI: 0.03–9.74, P = 0.499) and large sample size (OR = 0.53, 95% CI: 0.02–6.02, P = 0.617) showed trends potentially associated with reduced waste risk. Again, these associations were not statistically significant. The results indicate that none of the variables analyzed showed a statistically significant association with either publication status or research waste status. Table 3Univariable logistic regression analysis of the association of key study characteristics with publication status.EstimateSEOR (95%CI)Z P No. of arms 2Ref30.341.221.40 (0.06, 12.33)0.2760.782 No. of centers Single centerRefMulticenter−0.141.190.87 (0.04, 6.86)−0.1210.904 No. of participants <300Ref≥ 3000.690.942.00 (0.34, 15.94)0.7410.459 Region of PI European/AmericanRefNon-European/American−1.861.150.16 (0.01, 1.11)−1.6150.106 Primary purpose PreventionRefTreatment−0.091.210.92 (0.04, 7.82)−0.0720.943Others0.321.241.38 (0.06, 13.00)0.2560.798CI: confidence interval; No.: number; OR: odds ratio; PI: principal investigator; Ref: Reference; SE: standard error. Univariable logistic regression analysis of the association of key study characteristics with publication status. CI: confidence interval; No.: number; OR: odds ratio; PI: principal investigator; Ref: Reference; SE: standard error. Table 4Univariable logistic regression analysis of the association of key study characteristics with publication status waste situations.EstimateSEOR (95%CI)Z P No. of centers Single centerRefMulticenter−0.881.30.41 (0.03, 9.74)−0.6760.499 No. of participants <300Ref≥ 300−0.641.270.53 (0.02, 6.02)−0.5010.617 Region of PI European/AmericanRefNon-European/American0.751.272.12 (0.19, 48.07)0.5910.555 Primary purpose PreventionRefTreatment−1.431.490.24 (0.01, 6.65)−0.9610.337Others−1.831.510.16 (0.01, 4.58)−1.2110.226CI: confidence interval; No.: number; OR: odds ratio; PI: principal investigator; Ref: Reference; SE: standard error. Univariable logistic regression analysis of the association of key study characteristics with publication status waste situations. CI: confidence interval; No.: number; OR: odds ratio; PI: principal investigator; Ref: Reference; SE: standard error. Discussion Through a comprehensive analysis of RCTs on POCD, this study reveals significant imbalances in research design and translation efficiency within this field. Although research activity, particularly pharmacological intervention trials from Asia, is vigorous and heavily reliant on external funding, the proportion ultimately translated into publicly available evidence is extremely low, and research waste is prevalent. This exposes multiple issues in current research, including severe geographical publication bias, insufficient methodological rigor, and systemic translation barriers, highlighting the urgent need to optimize research resource allocation, strengthen academic publication fairness, and improve methodological quality18–20. The high concentration of trials on pharmacological interventions reflects that drug therapy is the mainstream direction in current POCD prevention and treatment research. However, it also suggests that exploration of non-pharmacological interventions—such as multimodal anesthesia, cognitive training, etc.—may lag, and that research diversity needs enrichment21,22. Furthermore, the overwhelming reliance on industry or other external funding underscores the field’s dependence on commercial capital, which may affect research independence, intervention selection, and ultimately, the accessibility of research outcomes. The dominance of single-center studies at the implementation level may limit the representativeness and generalizability of findings23,24. Notably, Asia has become the primary region initiating POCD RCTs, far surpassing North America and Europe, which may be related to rapid growth in surgical volumes, increased investment in clinical research, and the characteristics of ethical review processes in Asian countries. There is a significant disconnect between trial completion and result publication, with a publication rate of only 16.3% for completed trials, indicating severe under-publication. All published studies originated from North America, Europe, or other regions. In contrast, none of the completed trials from Asia were published by the cutoff date, a statistically significant difference. This clearly reveals significant geographical “publication bias” in POCD research25–27. The high number of trial registrations but low publication rate from Asia may be due to multiple factors, including language barriers, relatively less experience and competitiveness in publishing in high-impact international journals, lower motivation to publish negative or neutral results, or undetected systematic differences in research quality itself28. This phenomenon may lead to subsequent evidence-based decisions, such as systematic reviews and guideline development, failing to fully and accurately reflect the global, particularly Asian, research landscape and outcomes, affecting the comprehensiveness and representativeness of the evidence. The 7 published RCTs demonstrated good reporting completeness, largely adhering to the CONSORT statement, reflecting the common requirements of international medical journals for reporting standards and their positive impact. However, nearly half (3/7) of the published trials had design flaws. These flaws primarily stemmed from “other bias,” arising mainly from deviations from the predefined protocol during trial implementation and from inherent deficiencies in study design. Specifically, changes to primary outcome measures after patient enrollment had begun29, while potentially scientifically justified, increased the risk of outcome selection and reporting bias in the context of partially collected data, undermining the a priori certainty of the conclusions. Moreover, inadequate sample size design is a widespread structural issue. Some studies base their sample size calculations on feasibility rather than on the statistical standards required to evaluate clinical efficacy. This directly results in severely insufficient study power, making it impossible to detect the true clinical effects and thereby raising doubts about the reliability of the research conclusions30,31. The extremely high proportion of research waste in the POCD field highlights a severe mismatch between resource investment and knowledge output. This waste is not randomly distributed but is significantly concentrated in specific regions, as corroborated by the “publication status” results, indicating that trials originating from Asia face systemic barriers to translating outcomes, which may be an important reason for geographical bias in the global evidence base. However, logistic regression analysis failed to identify any single variable with a statistically significant association with either “research waste” or “publication status.” We believe this “negative” result does not negate the existence of the problem but profoundly reveals the complexity of the causes of research waste32,33. It indicates that whether wasted research is determined not by an isolated characteristic but by the intricate interplay of multiple factors like methodological rigor, team execution, institutional support systems, regional research culture, publication ecology, and deeper incentive mechanisms. Therefore, to effectively curb research waste in this field, we must move beyond optimizing single technical indicators and strive to build a systematic solution that encourages high-quality research, ensures process transparency, and guarantees that all research outcomes enter the public knowledge system fairly and promptly. To address these methodological deficiencies and bridge the gap between research output and evidence translation, we propose several concrete recommendations for future POCD research. First, to overcome the limitations of single-center studies and insufficient statistical power, researchers should prioritize well-designed multicenter trials with adequately powered sample sizes to ensure robust and generalizable findings34. Second, to combat the pervasive issue of non-publication, particularly for trials with negative or neutral results, the establishment of alternative publication platforms, such as registry-based journals or online repositories, is urgently needed to ensure all completed trials contribute to the evidence base. Finally, given the significant geographical imbalance in publication rates, fostering international collaboration is essential. High-risk regions, particularly in Asia, should partner with experienced institutions in North America and Europe to leverage local surgical volumes while adopting rigorous international standards for trial design, outcome measurement, and transparent reporting. Limitations This study has several limitations. First, the data source was limited to ClinicalTrials.gov, the largest clinical trial registry, but it did not capture all global POCD trials. Consequently, our findings reflect the characteristics of studies registered on this platform35. Second, the relatively small sample size of this study may have limited statistical power, resulting in observed associations not reaching statistical significance in the univariate regression analysis and limiting the ability to perform more in-depth multivariate analyses to control for confounding factors. Specifically, the wide 95%CI observed in our regression models suggests considerable uncertainty in the effect estimates. Third, during sample screening, we primarily used “Completion Date” as the criterion and did not actively exclude records marked as “Terminated,” “Withdrawn,” or “Unknown”36. This approach was based on two considerations. On one hand, the initial sample size of Phase III/IV RCTs in the field was limited, and over-exclusion would hinder analysis. On the other hand, “terminated” trials themselves often represent resource investments that failed to meet their intended goals and can be viewed as a form of research waste, while records with “unknown” status may also contain studies that are actually completed or even published37. Finally, the assessment of “design flaws” was primarily based on reported information in published articles and publicly available registry data; for unpublished trials, the true methodological quality may be underestimated or misjudged38. Conclusions This study is the first to systematically assess research waste in RCTs on POCD, revealing severe waste and significant geographical publication bias in this domain. Although research activity in Asia is vigorous, the rate of translation into published outcomes is extremely low. Moreover, nearly half of the published studies have methodological flaws. Univariate analysis did not identify any significant predictive variables, suggesting that research waste may stem from the complex interplay among multiple factors, including methodological rigor, execution quality, regional support systems, and publication ecology. Future research should focus on enhancing the overall efficiency of RCTs by promoting prospective trial registration, strengthening standardized assessment processes in multicenter collaborations, establishing dedicated publication channels for negative results and ineffective interventions, and providing methodological and international publication support to research teams in high-waste-risk regions, thereby systematically reducing resource waste. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions Conceptualization: Y.H. and Y.G. Methodology: Y.H., Y.G., and J.W. Formal analysis: J.L., and X.F. Data collection: J.Y., X.F., Q.Z., W.L. and Z.X. Data curation: J.Y., X.F., Q.Z., W.L. and Z.X. Writing- original draft: all authors. Writing- review and editing: all authors. Funding This work was supported by the Southwest Medical University Student Innovation and Entrepreneurship Project Fund (Grant Number: 2025012 and 2025008). Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jiyang Li and Xinxing Fei contributed equally to this work. Contributor Information Yaqian Gao, Email: 673509366@qq.com. Yue Hu, Email: huyue@swmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.